AVM Biotechnology, Inc., www.avmbiotech.com, founded 2008, privately held, HQ: Seattle, WA., series E; $35M round to bridge to sales; contact tdeisher@avmbiotech.com or tbertsch@avmbiotech.com

AVM Biotechnology's immunomodulatory lead small molecule, AVM0703, induces and mobilizes unique gamma delta TCR – invariant TCR double positive T lymphocytes and Natural Killer T-like cells. The molecule is distinguished clinically from other drugs approved or in trials for relapsed/refractory (R/R) heavily pretreated Non-Hodgkin's Lymphoma (NHL) by its long term survival and absence of safety signals. AVM plans to apply for accelerated approval in H1 2025 and conduct confirmatory trials in first line R/R NHL in combination with R-CHOP to address ABC subtype DLBCL resistance to R-CHOP and reduce the number of cycles of R-CHOP needed to obtain durable complete response, reducing or eliminating the cardiotoxicity and secondary malignancies that plague DLBCL survivors.

Comparison between AVM0703 and recent publications investigating new entity or combination trials.

Drug	Indication	Median Prior Lines	Approval Status	Kaplan Meier 24 month OS*	Grade 3+ drug-related AEs#	Grade 4+ drug-related AEs	CNS included
AVM0703 RP2D N=16	R/R NHL all aggressive subtypes	3 (2-8)	Phase 2	**60%**	27% of pts	**0**	**Y**
Brentuximab + Lenalidomide[1]	R/R DLBCL not double or triple hit N=37	3 (1-6)	Ph 1b/2	43%	94% of pts	not given#	N
Polatuzumab + Bendamustine + Rituximab[2]	R/R DLBCL N=106	2 (1-7)	Phase 1b/2	35%	80.8%	not given#	?
CD19-CD22 bispecific CarT + Pembrolizumab[3]	R/R LBCL N=52	3 (1-10)	Phase 1	40%	>61.5%##	not given 1 CarT related death	N
Polatuzumab + Bendamustine + Rituximab (package insert)[4] (Sehn 2022)	R/R DLBCL N=80	2 (1-7)	Accelerated approval	35-38%	87% of pts	24% grade 4 7% grade 5 (death)	?
Epcoritamab[5]	R/R DLBCL/LBCL N=157	3 (2-11)	Accelerated approval	Not available	27% of pts	Included 0.6% fatalities#	N
Glofitamab (+ mosunetuzumab)[6]	R/R DLBCL/LBCL N=127	3 (1-13)	Accelerated approval	*Indolent excluded* 24% PFS	43% of pts	not given#	N
Carfilzomib + RICE then HSCT or other[7]	R/R CD20+ DLBCL N=29	1 (1-2)	Phase 1	48%	>66%##	>66%##	N
Mosunetuzumab + Polatuzumab[8] (53% + PI choice)	R/R DLBCL/HGBCL N=98	3 (1-10)	Phase 2	48%	35%	not given#	N
Durvalumab + Rituximab + Bendamustine[10]	R/R DLBCL N=10	4	Phase 1	27%	>55%##	not given#	N

[1] Ward 2022; [2] Sehn 2022; [3] Roddie 2023; [4] Sehn 2022; [5] Thieblemont, 2023; [6] Hutchings, 2021; [7] Torka, 2023; [8] Budde, 2023; [9] Herrara, 2019; [10]Casulo, 2023 * PFS listed when OS not provided

AEs published as Grade 3+ or Grade 3/4 and Grade 4 not possible to separate out; ## only Treatment-emergent adverse events (TEAEs) listed

AVM
BIOTECHNOLOGY

1749 Dexter Avenue N | Seattle, WA 98109 | 206-906-9922 | info@avmbiotech.com | www.avmbiotech.com